Antibody Drug Conjugate Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Antibody Drug Conjugate market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Roche, Takeda, Gilead Sciences, Pfizer, GlaxoSmithKline, Daiichi Sankyo/AstraZeneca, Sorrento Therapeutics, Inc., Seagen Inc., Regeneron Pharmaceuticals, Gilead Sciences, RayzeBio, Inc., Seagen Inc., Bristol-Myers Squibb

[Nevada, United States] - DelveInsight's "Antibody Drug Conjugate Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Antibody Drug Conjugate, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Antibody Drug Conjugate Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/antibody-drug-conjugate-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Antibody Drug Conjugate Market Report:
The Antibody Drug Conjugate market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In September, 2024: Daiichi Sankyo announced that their study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer
In September, 2024: Merck Sharp & Dohme LLC announced that their clinical study will compare MK-2870 sacituzumab, tirumotecan to chemotherapy. The goal of the study is to learn if people who receive MK-2870 sacituzumab, tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.
In September, 2024: AstraZeneca announced that a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy
In September, 2024: Merck Sharp & Dohme LLC announced that the purpose of their study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations.
In September, 2024: Takeda announced that the purpose of their study is to assess the antitumor efficacy of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 weeks, as measured by the overall objective response rate (ORR) in patients with r/r sALCL following at least 1 multiagent chemotherapy regimen (cyclophosphamide, doxorubicin hydrochloride [hydroxydaunorubicin], vincristine sulfate [Oncovin], and prednisone [CHOP] or equivalent multiagent chemotherapy regimens with curative intent).
In September, 2024: RayzeBio, Inc. announced that a Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and with pembrolizumab in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
The ADC market is experiencing robust growth, with worldwide sales reported at $7.5 billion in 2022. This figure is projected to exceed $30 billion by 2028, reflecting a compound annual growth rate (CAGR) of approximately 25%​
A study highlighted the significant role of ADCs in treating conditions like triple-negative breast cancer (TNBC). For instance, sacituzumab tirumotecan, an ADC for TNBC, demonstrated a notable reduction in the risk of disease progression compared to traditional chemotherapy​
Currently, ADC development heavily focuses on tumor types such as non-small cell lung cancer, breast cancer, and ovarian cancer. Newer candidates are also being investigated for tumors with previously limited ADC applications, such as prostate cancer and chronic lymphocytic leukemia (CLL)
Key Antibody Drug Conjugate Companies are as follows: Roche, Takeda, Gilead Sciences, Pfizer, GlaxoSmithKline, Daiichi Sankyo/AstraZeneca, Sorrento Therapeutics, Inc., Seagen Inc., Regeneron Pharmaceuticals, Gilead Sciences, RayzeBio, Inc., Seagen Inc., Bristol-Myers Squibb
Key Antibody Drug Conjugate Therapies are as follow: ENHERTU (fam-trastuzumab deruxtecan-nxki), ADCETRIS (brentuximab vedotin), Tisotumab vedotin-tftv, Trastuzumab, deruxtecan, Enfortumab, vedotin, Trastuzumab, emtansine, Brentuximab, ABBV-399, HER3-DXd, deruxtecan, tazevibulin, ARX788, AZD8205, Farletuzumab, ecteribulin
Launching multiple stage Antibody Drug Conjugate pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Antibody Drug Conjugate market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/antibody-drug-conjugate-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Antibody Drug Conjugate Overview:
Antibody-drug conjugates (ADCs) comprise three main components: an antibody, a linker and a payload. The clinicalproperties of ADCs depend on the characteristics of all three of these components. Since the inception of ADCs, the basicapproach to designing and building these agents has remained constant.

Antibody Drug Conjugate Epidemiology Segmentation:
The Antibody Drug Conjugate market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Total incident cases of potential indications (Non-small Cell Lung Cancer, Hematologic malignancies [such as PTCL, CTCL, DLBCL, and others], Breast Cancer, Gynecologic cancer, and others) in the 7MM
Total Indication wise eligible cases in the 7MM Indication wise treatable cases in the 7MM

For more information about Antibody Drug Conjugate companies working in the treatment market, visit https://www.delveinsight.com/sample-request/antibody-drug-conjugate-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Antibody Drug Conjugate Market Insights
Antibody-drug conjugates (ADCs) are becoming increasingly prominent in the oncology landscape. More that ten ADCs aremarketed worldwide for hematological and solid tumor malignancies, of which seven have gained regulatory approval since 2019
Gemtuzumab ozogamicin (MYLOTARG, Pfizer), an anti-CD33 mAb-calicheamicin conjugate and the first ADC for oncology,was granted accelerated approval for relapsed CD33+ acute myeloid leukemia (AML) in 2000. The drug was withdrawn in2010 for toxicity and lack of efficacy in a Phase III trial, but the FDA approved a lower, fractionated dose in 2017. This drug is also approved in Japan and Europe
Trastuzumab emtansine (T-DM1; KADCYLA, Roche) was the first ADC to be approved for any solid tumor. This therapy is approved for early-stage and metastatic, HER2+ breast cancer
Sacituzumab govitecan (TRODELVY, Gilead Sciences), an anti-TROP2 mAb conjugated to SN-38, the active metabolite ofirinotecan, is approved for previously treated metastatic triple-negative breast cancer

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/antibody-drug-conjugate-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Antibody Drug Conjugate Therapies and Key Companies:
ENHERTU (fam-trastuzumab deruxtecan-nxki): AstraZeneca/Daiichi Sankyo
ADCETRIS (brentuximab vedotin): Pfizer (Seagen)/Takeda
Tisotumab vedotin-tftv: Genmab/Pfizer
Trastuzumab deruxtecan: Daiichi Sankyo/AstraZeneca
Enfortumab vedotin: Astellas
Trastuzumab emtansine: Roche
Brentuximab: Pfizer/ Takeda
ABBV-399: AbbVie
HER3-DXd: Daiichi Sankyo/Merck
deruxtecan: Merck
tazevibulin: Sutro Biopharma
ARX788: Ambrx
AZD8205: AstraZeneca
Farletuzumab, ecteribulin: Bristol-Myers Squibb

Antibody Drug Conjugate Epidemiology:
The landscape for antibody-drug conjugates (ADCs) is evolving rapidly, with significant insights emerging regarding their epidemiology and market potential. As of January 2024, there are 12 FDA-approved ADCs covering 16 indications, predominantly for various types of breast cancer, non-small cell lung cancer, and hematological malignancies such as lymphomas

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/antibody-drug-conjugate-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Antibody Drug Conjugate Market Drivers:
Rising Cancer Prevalence
Technological Advancements
Favorable Regulatory Environment
Increasing Healthcare Expenditure

Antibody Drug Conjugate Market Barriers:
High Development Costs
Side Effects and Safety Concerns
Limited Awareness and Acceptance
Regulatory Challenges

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/antibody-drug-conjugate-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Antibody Drug Conjugate Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Antibody Drug Conjugate Companies: Roche, Takeda, Gilead Sciences, Pfizer, GlaxoSmithKline, Daiichi Sankyo/AstraZeneca, Sorrento Therapeutics, Inc., Seagen Inc., Regeneron Pharmaceuticals, Gilead Sciences, RayzeBio, Inc., Seagen Inc., Bristol-Myers Squibb
Key Antibody Drug Conjugate Therapies: ENHERTU (fam-trastuzumab deruxtecan-nxki), ADCETRIS (brentuximab vedotin), Tisotumab vedotin-tftv, Trastuzumab, deruxtecan, Enfortumab, vedotin, Trastuzumab, emtansine, Brentuximab, ABBV-399, HER3-DXd, deruxtecan, tazevibulin, ARX788, AZD8205, Farletuzumab, ecteribulin
Antibody Drug Conjugate Therapeutic Assessment: Current marketed and emerging therapies
Antibody Drug Conjugate Market Dynamics: Antibody Drug Conjugate Market drivers and Antibody Drug Conjugate barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Antibody Drug Conjugate Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Antibody Drug Conjugate market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/antibody-drug-conjugate-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Executive Summary of Antibody Drug Conjugates (ADC)
4. Key Events
5. Antibody Drug Conjugates (ADC) Market Overview At A Glance
6. Background And Overview
7. Target Population
8. Antibody Drug Conjugates (ADC) Marketed Drugs
9. Antibody Drug Conjugates (ADC) Emerging Drugs
10. Antibody Drug Conjugates (ADC): The 7MM Analysis
11. Unmet Needs
12. SWOT Analysis
13. KOL Views
14. Market Access and Reimbursement
15. Appendix
16. Delveinsight Capabilities
17. Disclaimer
18. About DelveInsight

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.